Further Drug Development

Based on experience and the collaboration with partner experts from academic and corporate research and development DMG has commenced the evaluation of further new therapeutics projects.

DMG has commenced a thorough investigation and evaluation of potential drug development pipeline projects that build on the experience gained including therapeutics aiming at parasitic, bacterial and viral targets and employing new biological tools and approaches. Included in these approaches, the company is pursuing a strategy to protect the artemisinin derivatives, as the first line therapies for malaria, against the development of resistance. 
More information will be forthcoming in the near future.